Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Reuben

Showing results (51-60 of 133) with videos related to

Pageof 14
Sort By:
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Journal for Immunotherapy of Cancer|July 8, 2026
Unbiased avidity-based isolation of antigen-specific T cellsAmanda Montoya, Meredith L Frank, Peixin Jiang, et al.
Nature Communications|April 3, 2026
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signaturesNan Deng, Fahriye Duzagac, Ana M Bolivar, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Gastroenterology|January 20, 2024
Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for ImmunopreventionAna M Bolivar, Fahriye Duzagac, Nan Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
Pageof 14

Showing results (51-60 of 133) with videos related to

Sort By:
Pageof 14
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Journal for Immunotherapy of Cancer|July 8, 2026
Unbiased avidity-based isolation of antigen-specific T cellsAmanda Montoya, Meredith L Frank, Peixin Jiang, et al.
Nature Communications|April 3, 2026
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signaturesNan Deng, Fahriye Duzagac, Ana M Bolivar, et al.
Science Translational Medicine|April 3, 2020
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancerSumit K Subudhi, Luis Vence, Hao Zhao, et al.
Gastroenterology|January 20, 2024
Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for ImmunopreventionAna M Bolivar, Fahriye Duzagac, Nan Deng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to ChemotherapyToshiaki Iwase, Evan N Cohen, Hui Gao, et al.
Pageof 14